---
layout: default
title: Durvalumab
description: "Durvalumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 65
evidence_level: L3
indication_count: 10
---

# Durvalumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Durvalumabï¼šå¾éå°ç´°èƒè‚ºç™Œåˆ°æ³Œå°¿é“ä¸Šçš®ç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Durvalumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Durvalumab åŸæœ¬ç”¨æ–¼æ²»ç™‚éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€è†½é“ç™Œã€è‚ç´°èƒç™ŒåŠå­å®®å…§è†œç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ³Œå°¿é“ä¸Šçš®ç™Œ (urothelial carcinoma)** ç›¸é—œè…«ç˜¤æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **å¤šå€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€è†½é“ç™Œã€è‚ç´°èƒç™Œã€å­å®®å…§è†œç™Œã€è†€èƒ±ç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | prostatic urethra urothelial carcinomaã€kidney pelvis sarcomatoid transitional cell carcinomaã€infiltrating bladder urothelial carcinoma sarcomatoid variantã€renal pelvis papillary urothelial carcinomaã€transitional cell carcinomaã€uterine ligament adenocarcinomaã€endocervical carcinomaã€adenoid cystic carcinoma of the cervix uteriã€uterine ligament serous adenocarcinomaã€signet ring cell variant cervical mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.98% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 13 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. prostatic urethra urothelial carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Durvalumab æ˜¯ä¸€ç¨® PD-L1 æŠ‘åˆ¶åŠ‘ï¼Œé€éé˜»æ–· PD-L1 èˆ‡ PD-1/CD80 çš„çµåˆï¼Œ</p>
<p>æ¢å¾© T ç´°èƒå°è…«ç˜¤ç´°èƒçš„å…ç–«ç›£è¦–åŠŸèƒ½ã€‚æ³Œå°¿é“ä¸Šçš®ç™Œé€šå¸¸è¡¨ç¾è¼ƒé«˜çš„ PD-L1 è¡¨ç¾ï¼Œ</p>
<p>ä¸”å·²æœ‰å…¶ä»– PD-1/PD-L1 æŠ‘åˆ¶åŠ‘åœ¨æ³Œå°¿é“ä¸Šçš®ç™Œç²å¾—æ ¸å‡†ã€‚</p>
<p>Durvalumab å·²æ ¸å‡†ç”¨æ–¼è‚Œè‚‰ä¾µçŠ¯å‹è†€èƒ±ç™Œçš„å‰å°æ€§æ²»ç™‚ï¼Œ</p>
<p>å…¶ç™‚æ•ˆå¯èƒ½å»¶ä¼¸è‡³å…¶ä»–éƒ¨ä½çš„æ³Œå°¿é“ä¸Šçš®ç™Œã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT02812420">NCT02812420</a></td>
<td>Phase 1</td>
<td>ACTIVE_NOT_RECRUITING</td>
<td>54</td>
<td>è©•ä¼° durvalumab+tremelimumab åœ¨ç„¡æ³•æ¥å— cisplatin çš„é«˜é¢¨éšªæ³Œå°¿é“ä¸Šçš®ç™Œè¡“å‰æ²»ç™‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03912818">NCT03912818</a></td>
<td>Phase 2</td>
<td>TERMINATED</td>
<td>7</td>
<td>è©•ä¼° durvalumab è¯åˆæ–°è¼”åŠ©åŒ–ç™‚åœ¨è®Šç•°çµ„ç¹”å‹è†€èƒ±ç™Œçš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03452332">NCT03452332</a></td>
<td>Phase 1</td>
<td>COMPLETED</td>
<td>20</td>
<td>ä½åˆ†æ¬¡æ”¾ç™‚è¯åˆ durvalumab å’Œ tremelimumab æ²»ç™‚å¾©ç™¼/è½‰ç§»æ€§å©¦ç§‘ç™Œç—‡</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04065269">NCT04065269</a></td>
<td>Phase 2</td>
<td>RECRUITING</td>
<td>174</td>
<td>ATARI è©¦é©—ï¼šATR æŠ‘åˆ¶åŠ‘è¯åˆ olaparib/durvalumab æ²»ç™‚ ARID1A ç¼ºå¤±å©¦ç§‘ç™Œç—‡</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/37467967/">37467967</a></td>
<td>2023</td>
<td>Review</td>
<td>Biomed J</td>
<td>å­å®®é ¸å°ç´°èƒç¥ç¶“å…§åˆ†æ³Œç™Œçš„åˆ†å­åŸºç¤å’Œæ²»ç™‚é€²å±•ï¼ŒåŒ…æ‹¬ durvalumab çš„æ‡‰ç”¨</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. kidney pelvis sarcomatoid transitional cell carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02812420" target="_blank">NCT02812420</a></td><td>EARLY_PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>54</td><td>A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. infiltrating bladder urothelial carcinoma sarcomatoid variant</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02812420" target="_blank">NCT02812420</a></td><td>EARLY_PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>54</td><td>A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03912818" target="_blank">NCT03912818</a></td><td>PHASE2</td><td>TERMINATED</td><td>7</td><td>Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. renal pelvis papillary urothelial carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. uterine ligament adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. endocervical carcinoma</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03452332" target="_blank">NCT03452332</a></td><td>PHASE1</td><td>COMPLETED</td><td>20</td><td>Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04065269" target="_blank">NCT04065269</a></td><td>PHASE2</td><td>RECRUITING</td><td>174</td><td>ATARI: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynae...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37467967/" target="_blank">37467967</a></td><td>2023</td><td>Article</td><td>Biomedical journal</td><td>Small cell neuroendocrine carcinoma of the cervix: From mole...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. adenoid cystic carcinoma of the cervix uteri</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. uterine ligament serous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. signet ring cell variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. intestinal variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001088è™Ÿ | æŠ‘ç™Œå¯§æ³¨å°„åŠ‘ | æ³¨å°„åŠ‘ | éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€è†½é“ç™Œã€è‚ç´°èƒç™Œã€å­å®®å…§è†œç™Œã€è†€èƒ±ç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å…ç–«æ²»ç™‚ (PD-L1 æŠ‘åˆ¶åŠ‘) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | ä½åº¦ |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | ç”²ç‹€è…ºåŠŸèƒ½ã€è‚è…åŠŸèƒ½ã€å…ç–«ç›¸é—œä¸è‰¯åæ‡‰ |
| è™•ç½®é˜²è­· | æ¨™æº–ç”Ÿç‰©è£½åŠ‘è™•ç½®è¦ç¯„ |

## å®‰å…¨æ€§è€ƒé‡

- **å…ç–«ç›¸é—œä¸è‰¯åæ‡‰**ï¼šè‚ºç‚ã€è‚ç‚ã€çµè…¸ç‚ã€å…§åˆ†æ³Œç—…è®Šã€çš®ç–¹
- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - èˆ‡çš®è³ªé¡å›ºé†‡ï¼ˆHydrocortisoneã€Dexamethasoneã€Prednisone ç­‰ï¼‰æœ‰ä¸­åº¦äº¤äº’ä½œç”¨
  - èˆ‡ Adalimumab æœ‰é‡å¤§äº¤äº’ä½œç”¨
- **ç‰¹æ®Šæ—ç¾¤**ï¼šè‡ªé«”å…ç–«ç–¾ç—…æ‚£è€…éœ€è¬¹æ…ä½¿ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Adrenal Insufficiency** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Colitis** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Infections** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Thyroid Diseases** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Pneumonia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Durvalumab å·²æ ¸å‡†ç”¨æ–¼è†€èƒ±ç™Œï¼Œä¸” PD-L1 æŠ‘åˆ¶åŠ‘åœ¨æ³Œå°¿é“ä¸Šçš®ç™Œçš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ã€‚
é æ¸¬é©æ‡‰ç—‡èˆ‡åŸé©æ‡‰ç—‡å…·æœ‰ç›¸åŒçµ„ç¹”å­¸ç‰¹å¾µå’Œå…ç–«å­¸æ©Ÿè½‰ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ä¸åŒéƒ¨ä½æ³Œå°¿é“ä¸Šçš®ç™Œçš„ç™‚æ•ˆè©•ä¼°
- PD-L1 è¡¨ç¾æ°´å¹³èˆ‡ç™‚æ•ˆçš„ç›¸é—œæ€§ç ”ç©¶
- èˆ‡å…¶ä»–å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘çš„é ­å°é ­æ¯”è¼ƒè©¦é©—

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Vitamin E]({{ "/drugs/vitamin_e/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Vinorelbine]({{ "/drugs/vinorelbine/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Propantheline]({{ "/drugs/propantheline/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Durvalumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/durvalumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_durvalumab,
  title = {Durvalumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/durvalumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
